IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Cancer Research

• Publication date

  2018-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-3573PMID 29500275PMCID PMC5984675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.

  2017influential reference
• IMMU-15. PD-1 BLOCKADE ACTIVATES CD4 T CELLS AND THE INNATE IMMUNE RESPONSE FOR GLIOBLASTOMA ERADICATION

  2017cited by this paper
• Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival

  2017cited by this paper
• OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

  2017cited by this paper
• Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

  2017cited by this paper
• Management of glioblastoma in elderly patients.

  2017influential reference
• Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

  2017cited by this paper
• PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis

  2016cited by this paper
• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

  2016influential reference
• Advanced age negatively impacts survival in an experimental brain tumor model.

  2016cited by this paper
• PD-L1 expression and prognostic impact in glioblastoma.

  2016influential reference
• Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

  2016cited by this paper
• ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143

  2016cited by this paper
• Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

  2016cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

  2014cited by this paper
• Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

  2014cited by this paper
• Regulation of re-myelination and/or myelin repair by methyl CpG binding protein 2 and brain derived neurotrophic factor in an experimental autoimmune encephalomyelitis model of multiple sclerosis

  2014cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• Psychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovations.

  2013cited by this paper
• Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities Temperature Matters! And Why It Should Matter to Tumor Immunologists

  2013cited by this paper
• IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

  2012cited by this paper
• Glioblastoma survival in the United States before and during the temozolomide era

  2012cited by this paper
• Accumulation of resident and peripheral dendritic cells in the aging CNS.

  2012cited by this paper
• Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

  2011cited by this paper
• The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.

  2011cited by this paper
• Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines.

  2009cited by this paper
• Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

  2007influential reference
• Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

  2007cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• B7-homolog 1 expression by human glioma: a new mechanism of immune evasion

  2005cited by this paper
• Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

  2004cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Indoleamine 2,3-dioxygenase. Equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes.

  1980cited by this paper

• Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies

  2026cites this paper
• Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion

  2026cites this paper
• Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications

  2026cites this paper
• Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy

  2026cites this paper
• Radiotherapy as an immunomodulator in cancer: Synergy with immunotherapy and roadmap for optimization

  2026cites this paper
• Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1

  2025cites this paper
• Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance

  2025cites this paper
• Multiple radiations and its effect on biological system – a review on in vitro and in vivo mechanisms

  2025cites this paper
• Targeting the kynurenine pathway in gliomas: Insights into pathogenesis, therapeutic targets, and clinical advances.

  2025cites this paper
• A patent review of IDO1 inhibitors for cancer (2023 – present): an update

  2025cites this paper
• Tryptophan metabolism: From physiological functions to key roles and therapeutic targets in cancer (Review)

  2025cites this paper
• Immunotherapy for High-Grade Gliomas

  2025cites this paper
• The Metabolic Orchestration of Immune Evasion in Glioblastoma: From Molecular Perspectives to Therapeutic Vulnerabilities

  2025cites this paper
• Glioblastoma at the crossroads: current understanding and future therapeutic horizons

  2025cites this paper
• New Insights into Monocyte-Derived Macrophages in Glioblastoma

  2025cites this paper
• Impact of gastrointestinal dysbiosis on tryptophan metabolism and neurological cancer progression

  2025cites this paper
• Effects of aging on anticancer therapy in murine cancer models

  2025cites this paper
• Immunologic specificity in glioblastoma: Antigen discovery and translational implications

  2025cites this paper
• Cellular Potency Optimization of Novel Heme-Binding Imidazo[5,1-b]thiazoles, Imidazo[1,5-a]pyridines and Pyrazines as Potent IDO1 Inhibitors Devoid of Cytochrome P450 Inhibition.

  2025cites this paper
• Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205

  2025cites this paper
• The promise of immunotherapy for central nervous system tumours

  2025cites this paper
• Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

  2025cites this paper
• Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma

  2025cites this paper
• Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update

  2025cites this paper
• The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy

  2025cites this paper
• Enhanced glioblastoma immunotherapy via SMAC mimetic dose escalation and TGFβ blockade

  2025cites this paper
• Astrocytes in glioblastoma tumor microenvironment.

  2025cites this paper
• Tryptophan metabolism in tumor microenvironment and therapeutic Implications.

  2025cites this paper
• Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)

  2025cites this paper
• Preoperative Peripheral Blood Serotonin and Kynurenine Levels Are Associated With Oncological Outcomes in Glioblastoma IDH-wt Patients

  2025cites this paper
• Immunomodulatory mechanisms driving tumor escape in Glioblastoma: the central role of IDO and tryptophan metabolism in local and systemic immunotolerance.

  2025cites this paper
• Regulatory T Cell Metabolism: A Promising Therapeutic Target for Cancer Treatment?

  2025cites this paper
• Glioblastoma Therapy: Past, Present and Future

  2024cites this paper
• A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

  2024cites this paper
• AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma

  2024cites this paper
• In Vivo Mouse Models for Adult Brain Tumors: Exploring Tumorigenesis and Advancing Immunotherapy Development.

  2024cites this paper
• Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.

  2024cites this paper
• IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

  2024cites this paper
• UCHL3 induces radiation resistance and acquisition of mesenchymal phenotypes by deubiquitinating POLD4 in glioma stem cells

  2024cites this paper
• Immunotherapy for head and neck cancer: Fundamentals and therapeutic development.

  2024cites this paper
• Hydrogels containing KYNA promote angiogenesis and inhibit inflammation to improve the survival rate of multi-territory perforator flaps.

  2024cites this paper
• Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy

  2024cites this paper
• Glioblastoma patients’ survival and its relevant risk factors during the pre-COVID-19 and post-COVID-19 pandemic: real-world cohort study in the USA and China

  2024cites this paper
• New progress in the treatment of diffuse midline glioma with H3K27M alteration

  2024cites this paper
• Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment

  2024cites this paper
• Activated kynurenine pathway metabolism by YKL-40 establishes an inhibitory immune microenvironment and drives glioblastoma development

  2024cites this paper
• Blocking feedback immunosuppression of antigen presentation in brain tumor during oncolytic virotherapy with oHSV-mshPKR.

  2024cites this paper
• Integrated analysis of bulk and single-cell RNA sequencing reveals the impact of nicotinamide and tryptophan metabolism on glioma prognosis and immunotherapy sensitivity

  2024cites this paper
• Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?

  2024cites this paper
• Research progress and challenges of the PD-1/PD-L1 axis in gliomas

  2024cites this paper
• Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence

  2023influential citation
• Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer

  2023cites this paper
• Translational Models in Glioma Immunotherapy Research

  2023cites this paper
• Radiation dose, schedule and novel systemic targets for radio-immunotherapy combinations.

  2023cites this paper
• Combined Inhibition of Indolamine-2,3-Dioxygenase 1 and C-X-C Chemokine Receptor Type 2 Exerts Antitumor Effects in a Preclinical Model of Cervical Cancer

  2023cites this paper
• Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population

  2023cites this paper
• Metabolic partitioning in the brain and its hijacking by glioblastoma

  2023cites this paper
• Prognostic evaluation of patients with glioblastoma using a new score prediction model.

  2023cites this paper
• The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma

  2023cites this paper
• The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches

  2023cites this paper
• The kynurenine pathway implicated in patient delirium: possible indications for indoleamine 2,3 dioxygenase inhibitors

  2023cites this paper
• The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors.

  2023cites this paper
• Mechanisms Involved in the Therapeutic Effect of Cannabinoid Compounds on Gliomas: A Review with Experimental Approach.

  2023cites this paper
• Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies.

  2023cites this paper
• PPRX-1701, a nanoparticle formulation of 6′-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models

  2023cites this paper
• Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1+ CAFs-secreted Kyn/AhR/IL-6 and pol ζ-prevented CIN in human oral squamous cell carcinoma.

  2023cites this paper
• Tryptophan-Starved Human Cells Overexpressing Tryptophanyl-tRNA Synthetase Enhance High-Affinity Tryptophan Uptake via Enzymatic Production of Tryptophanyl-AMP

  2023cites this paper
• Assessment of the clinical effectiveness and safety of immune checkpoint inhibitors for glioblastoma: A systematic review

  2023cites this paper
• Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma

  2022cites this paper
• Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

  2022cites this paper
• Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.

  2022cites this paper
• The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies

  2022cites this paper
• Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity

  2022cites this paper
• Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio.

  2022cites this paper
• Glioma targeted therapy: insight into future of molecular approaches

  2022cites this paper
• Advances in Immunotherapies for Gliomas

  2022cites this paper
• AHR Agonist ITE Boosted PD1 Antibody’s Effects by Inhibiting Myeloid-Derived Cells Suppressive Cells in an Orthotopic Mouse Glioma Model

  2022cites this paper
• Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy

  2022cites this paper
• Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy

  2022cites this paper
• Systematic Analysis of a Pyroptosis-Related Signature to Predict the Prognosis and Immune Microenvironment of Lower-Grade Glioma

  2022cites this paper
• An integrated cytokine and kynurenine network as the basis of neuroimmune communication

  2022cites this paper
• Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma

  2022cites this paper
• Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy.

  2022cites this paper
• RETRACTED ARTICLE: Kynurenine promotes neonatal heart regeneration by stimulating cardiomyocyte proliferation and cardiac angiogenesis

  2022cites this paper
• The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis

  2022cites this paper
• Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer.

  2022cites this paper
• Current therapeutic options for glioblastoma and future perspectives

  2022cites this paper
• Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation

  2022cites this paper
• Current Trends in Immuno-Oncology.

  2022cites this paper
• Next Steps for Immunotherapy in Glioblastoma

  2022influential citation
• In Situ Dendritic Cell Recruitment and T Cell Activation for Cancer Immunotherapy

  2022cites this paper
• The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies

  2022cites this paper
• Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma

  2022cites this paper
• Neoadjuvant Immunotherapy in Gastrointestinal Cancers - The New Standard of Care?

  2022cites this paper
• Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor

  2021cites this paper
• What is New in Neuro-oncology?

  2021cites this paper
• GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer

  2021cites this paper
• Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme

  2021cites this paper
• Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection

  2021cites this paper
• Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor.

  2021cites this paper